Welcome to our dedicated page for NYSE news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NYSE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NYSE's position in the market.
On February 24, 2023, Hugoton Royalty Trust (HGTXU) announced the outcome of a special unitholder meeting held on February 23, 2023. Unitholders approved the appointment of Argent Trust Company as the successor trustee, contingent upon Simmons Bank's resignation. However, related amendments to the Trust's indenture did not receive enough votes for approval. The effective date for Simmons Bank's resignation depends on the fulfillment of certain conditions outlined in the trustee's notice. The press release also includes forward-looking statements that emphasize the uncertainty surrounding the transition and potential implications for the Trust's future operations.
Actinium Pharmaceuticals (NYSE: ATNM) reported positive survival data from its Actimab-A and CLAG-M combination trial for relapsed or refractory acute myeloid leukemia (AML) patients. Key findings include a 59% one-year overall survival for patients previously treated with Venetoclax, 75% measurable residual disease negativity, and a manageable safety profile. Notably, patients with a TP53 mutation showed a 52% one-year overall survival. These results were shared at the 64th Annual ASH Meeting, emphasizing the potential of Actimab-A as a treatment for high-risk AML patients previously deemed difficult to treat.
BARK, Inc. (NYSE: BARK) appointed Aarti Sharma as the new Chief People Officer, effective November 7, 2022. With 20 years in HR and people strategy, Sharma previously served as Global Head of HR at Cambium Networks, where she was key in its IPO. She aims to enhance BARK’s HR functions including talent acquisition and employee engagement. BARK, recognized as one of Newsweek’s Top 100 Most Loved Workplaces, continues to focus on employee satisfaction alongside its mission to bring joy to dogs. Sharma holds degrees in Statistics and an MBA.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced positive results from its pivotal Phase 3 SIERRA trial of Iomab-B for treating elderly patients with active relapsed or refractory acute myeloid leukemia (AML). The trial met its primary endpoint, achieving a durable complete remission (dCR) of 6 months post-treatment, with a p-value of <0.0001. Iomab-B demonstrated significant potential to increase patient access to bone marrow transplants (BMT) and improve patient outcomes, prompting the company to advance its Biologics License Application (BLA) submission to the FDA.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced a senior-level expansion of its clinical organization, strengthening its expertise in bone marrow transplant and acute myeloid leukemia. Key hires include Madhuri Vusirikala, MD, Akash Nahar, MD, Patrik Brodin, Ph.D., and Elaina Haeuber, enhancing the company's operational capabilities for pivotal programs Iomab-B and Actimab-A. Topline data from the Phase 3 SIERRA trial for Iomab-B is expected in Q4 2022. This expansion aims to advance clinical development and improve patient outcomes in hematological malignancies.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the virtual Bio-Europe conference from November 2-4, 2022. The event is the largest biopharma partnering meeting in Europe, featuring over 4,000 attendees and 27,000 scheduled 1-on-1 meetings. Actinium's business development team will conduct individual meetings, which can be requested through the partneringONE® system. The company focuses on targeted radiotherapies for cancer treatment, with key products including I-131 apamistamab (Iomab-B) and Actimab-A, both undergoing clinical trials.
Actinium Pharmaceuticals (NYSE: ATNM) provided a corporate update on September 21, 2022, highlighting key upcoming milestones in its clinical pipeline. Key data releases expected include topline results from the pivotal Phase 3 SIERRA trial for Iomab-B and overall survival data from the Actimab-A CLAG-M combination trial, both anticipated in Q4 2022. The company reported approximately $116 million in cash and equivalents as of Q2 2022, sufficient to support operations through mid-2025, facilitating its commitment to advancing targeted radiotherapies for patients with high unmet medical needs.
Volta Inc. (NYSE: VLTA) is set to release its first quarter 2022 results on Friday, May 13, 2022, before market open. This announcement will be followed by a conference call at 8:00 a.m. Eastern Time. Investors can listen to the call through the Investor Relations section of Volta's website or via telephone. A replay of the call will be available approximately three hours after it concludes, lasting until May 27, 2022. Volta is a leading provider of commerce-centric EV charging networks, aiming to support the transition to electric mobility.
Summary not available.
Horace Mann Educators Corporation (NYSE:HMN) will release its fourth-quarter and full-year 2021 results on February 1, after market close. A conference call to discuss these results is scheduled for February 2 at 10 a.m. ET. The financial information will be available on the company’s investor website. Founded in 1945, Horace Mann is dedicated to providing financial services tailored for educators, emphasizing its mission to help them achieve lifelong financial success.